written on 20.03.2014

AstraZeneca unveils direct-to-patient Nexium sales to fend off generic rivals


AstraZeneca is staring down the barrel of its Nexium patent loss, but it's doing its best to dodge the bullet. In a bid to keep patients hooked on the branded version of that purple pill, the company will sell Nexium to them directly–and at a discount.